Table 2

Main baseline features in the eight patients meeting ASAS criteria [32] for peripheral spondyloarthritis

Patient 14

Patient 15

Patient 16

Patient 17

Patient 18

Patient 19

Patient 20

Patient 21


Type of SpA

AS

AS

AS

AS

uSpA

uSpA

PsA

PsA

Sacroiliitis

Grade 2

Grade 3

Grade 3

Grade 3

Grade 0

Grade 1

Grade 0

Grade 0

HLA-B27

+

-

+

+

+

+

-

-

Gender

Male

Female

Male

Female

Female

Female

Female

Female

Disease duration (years)

8

15

19

6

10

10

10

20

Main articular and extraarticular symptoms

Coxitis, arthritis

Arthritis

Arthritis, uveitis

Peripheral enthesitis (Achilles tendon, knee, elbow), arthritis, chest pain

Arthritis

Arthritis, IBD, uveitis

Arthritis, dactylitis, psoriasis, uveitis

Arthritis, psoriasis

Concomitant NSAIDs/steroids (dosage)

Yes/no

No/yes (20 mg/day)

Yes/yes (5 mg/day)

Yes/yes (15 mg/day)

Yes/yes (8 mg/day)

No/yes (10 mg/day)

Yes/yes (20 mg/day)

Yes/yes (20 mg/day)

Concomitant DMARDs

Methotrexate

No

Methotrexate

Leflunomide

Methotrexate

Methotrexate

Methotrexate

Methotrexate

Previous biologics other than anti-TNF

No

Anakinra

No

Abatacept

No

No

No

No


AS, ankylosing spondylitis meeting modified New York criteria [33]; ASAS, Assessment of SpondyloArthritis International Society; DMARD, disease-modifying antirheumatic drug; IBD, inflammatory bowel disease; NSAID, nonsteroidal anti-inflammatory drug; PsA, psoriatic arthritis meeting Classification Criteria for Psoriatic Arthritis [36]; SpA, spondyloarthritis; uSpA, undifferentiated spondyloarthritis.

Lekpa et al. Arthritis Research & Therapy 2012 14:R53   doi:10.1186/ar3766

Open Data